Organoids were derived using the human Tumor Dissociation Kit (Miltenyi Biotec) from the ER+ patient derived xenografts from the Breast Cancer Genome Guided Therapy Study according to a previously described protocol (15 (link)). Organoids were cultured in 96-well low binding NanoCulture plate (Organogenix) in DMEM supplemented with 10% FCS, 1% glutamax, 1% sodium pyruvate, non-essential amino acids, and 1% Penicillin-Streptomycin (Life Technologies) at 37°C, 5% CO2. Organoid growth was measured as previously described (15 (link)) using the CellTiter-Glo Viability assay (Promega).